Trending Now
We have updated our Privacy Policy and Terms of Use for Eurasia Group and its affiliates, including GZERO Media, to clarify the types of data we collect, how we collect it, how we use data and with whom we share data. By using our website you consent to our Terms and Conditions and Privacy Policy, including the transfer of your personal data to the United States from your country of residence, and our use of cookies described in our Cookie Policy.
{{ subpage.title }}
The logo for Isomorphic Labs is displayed on a tablet in this illustration.
Meet Isomorphic Labs, the Google spinoff that aims to cure you
In 2024, Demis Hassabiswon a Nobel Prize in chemistry for his work in predicting protein structures through his company, Isomorphic Labs. The lab, which broke off from Google's DeepMind in 2021, raised $600 million from investors in a new funding round led by Thrive Capital on Monday. The company did not disclose a valuation.
Isomorphic uses artificial intelligence to discover new drugs through its AlphaFold technology, which was at the center of Hassabis’s Nobel win last year. Ultimately, Hassabis wants to do something that’s not exactly simple: He’s vowed to “solve all disease with the help of AI.”
Isomorphic is already working with big pharmaceutical companies such as Eli Lilly and Novartis, inking deals with the two drugmakers last year worth $3 billion. It plans to use the new money to improve its AI tools and to move its drugs toward clinical testing.